TBPH Q4 2024 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+6.8% YoY

Gross Profit

$19M100.0% margin

Operating Income

-$9M-49.1% margin

Net Income

-$16M-82.8% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+11.2%

Cash Flow

Operating Cash Flow

-$902,000

Free Cash Flow

-$1M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$354M

Total Liabilities

$179M

Stockholders' Equity

$176M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$18M	+6.8%
Gross Profit	$19M	$9M	+102.7%
Operating Income	-$9M	-$6M	-47.4%
Net Income	-$16M	-$9M	-82.5%

Revenue Segments

YUPELRI Monotherapy

$23M100%